U.S. Customs and Border Protection officers in Cincinnati recently seized more shipments containing unapproved medications.

Customs and Border Protection officers will continue to work with the trade industry and our consumer safety partners to ...

Both companies have been struggling to meet massive demand for their products – Zepbound and Wegovy are both on the FDA's list of medicines in short supply – and a simpler-to-produce vial ...

Since the start of summer, officers at the port of Cincinnati have seized several unapproved shipments of the weight loss drugs Ozempic, Wegovy and Trulicity ... The shipment contained 20 vials of ...

Wegovy Q3 sales total $2.5 bln Beat forecast but group sales weaker than expected Results soothe investor worries over slowing obesity drug demand Shares rose nearly 9%, but later reversed course ...

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago. GLP-1 agonist Wegovy ...

Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Wegovy sales soared 81% YoY to DKK17.3 billion; Obesity care grew 55%, while insulin sales rose 10%, boosting overall portfolio strength. The global sales increased 21% year over year (up 23% at ...

Also Read: Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug Insulin sales increased by 10% at CER to 12.51 billion Danish kroner, and rare disease sales increased by 17% at CER ...